<DOC>
	<DOCNO>NCT00976508</DOCNO>
	<brief_summary>This Phase 1 study investigate safety tolerability Figitumumab plus Pegvisomant treatment advance solid tumor .</brief_summary>
	<brief_title>Figitumumab Combined With Pegvisomant For Advanced Solid Tumors</brief_title>
	<detailed_description>This study close enrollment 18 April 2011 due inability recruit patient timely basis well business reason . Study closure relate safety concern .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients ≥18 year age advance solid tumor combination figitumumab pegvisomant reasonable treatment option . Patients age 10 18 year advance sarcoma available curative therapy therapy proven prolong survival acceptable quality life include Sarcoma Expansion Cohort . Adequate recovery prior therapy . Adequate organ function ( i.e . bone marrow , kidney , liver ) Total IGF1 ≥100 ng/ml ( 13 nmol/L ) . Concurrent treatment antitumor agent . Pregnant breastfeeding female . Significant past history active cardiac disease Active infection History diabetes mellitus . Glycosylated hemoglobin &gt; 5.7</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>advanced solid tumor cancer refractory cancer figitumumab pegvisomant</keyword>
</DOC>